30 SELECTED PUBLICATIONS BY CGTG MEMBERS
  1. Hemminki A, Peltomäki P, Mecklin J-P, Järvinen H, Salovaara R, Nyström-Lahti M, de la Chapelle A & Aaltonen LA
    Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer
    Nature Genet 1994; 8: 405-410.
  2. Hemminki A, Tomlinson I, Markie D, Järvinen H, Sistonen P, Björkqvist A-M, Knuutila S, Salovaara R, Bodmer W, Shibata D, de la Chapelle A & Aaltonen LA
    Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis
    Nature Genet 1997; 15: 87-90.
  3. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Höglund P, Järvinen H, Kristo P, Pelin K, Ridanpää M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A & Aaltonen LA
    A Serine/Threonine Kinase Gene Defective In Peutz-Jeghers Syndrome
    Nature 1998; 391: 184-187.
  4. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomäki P, Chadwick RB, Percesepe A, Kääriäinen H, Ahtola H, Eskelinen M, Härkönen N, Julkunen R, Kangas E, Ojala S, Tulikoura J, Valkamo E, Järvinen H, Mecklin J-P, de la Chapelle A
    Incidence of hereditary nonpolyposis colorectal cancer, and molecular screening for the disease
    New Eng J Med 1998; 338: 1481-7.
  5. Hemminki A, Mecklin J-P, Jarvinen H, Aaltonen L-A, Joensuu H
    Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy
    Gastroenterology, 2000; 119: 921-8.
  6. Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, Curiel DT.
    Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule
    Cancer Res, 2001; 61: 6377-81.
  7. Hemminki A, Belousova N, Zinn KR, Liu B, Wang M, Chaudhuri TR, Rogers BE, Buchsbaum DJ, Siegal GP, Barnes MN, Gomez-Navarro J, Curiel DT, Alvarez RD.
    An infectivity enhanced adenovirus allows in vivo imaging, circumvents deficiency of native receptor, and mediates molecular chemotherapy of ovarian cancer.
    Mol Ther, 2001; 4: 223-31.
  8. Kanerva A, Mikheeva G, Krasnykh VN, Coolidge CJ, Lam JT, Mahasreshti P, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT.
    Targeting Adenovirus to the Serotype 3 Receptor Increases Gene Transfer Efficiency to Ovarian Cancer Cells.
    Clin Cancer Res, 2002; 8: 275-80.
  9. Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Alemany R, Curiel DT, Hemminki A
    A Tropism Modified Oncolytic Adenovirus for Treatment of Ovarian Cancer
    Cancer Res, 2002; 62: 1266-70.
  10. Hemminki A, Zinn KR, Liu B, Chaudhuri TR, Desmond RA, Rogers BE, Barnes MN, Alvarez RD, Curiel DT
    In vivo molecular chemotherapy and non-invasive imaging with an infectivity enhanced adenovirus
    J Natl Cancer Inst, 2002; 94: 741-9.
  11. Kanerva A, Wang M, Bauerschmitz GJ Lam JT, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A
    Gene transfer to ovarian cancer versus normal tissues with fiber modified adenoviruses
    Mol Ther, 2002; 5: 695-704.
  12. Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, Wang M, Desmond RA, Keriel A, Barnett B, Baker HJ, Siegal GP, Curiel DT.
    A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model.
    Mol Ther, 2003; 7: 163-73.
  13. Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP, Curiel DT
    Modulation of Coxsackie-Adenovirus Receptor Expression for Increased Adenoviral Transgene Expression
    Cancer Res, 2003; 63: 847-53.
  14. Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, Cao Z, Alvarez RD, Curiel DT, Hemminki A
    Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus
    Mol Ther. 2003 ;8:449-58.
  15. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen L, Zou W
    Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
    Nature Med, 2003; 9: 562-7.
  16. Kanerva A, Bauerschmitz GJ, Yamamoto M, Lam JT, Alvarez RD, Siegal GP, Curiel DT, Hemminki A
    A Cyclooxygenase-2 Promoter Based Conditionally Replicating Adenovirus with Enhanced Infectivity for Treatment of Ovarian Adenocarcinoma
    Gene Ther, 2004;11: 552-9 .
  17. Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R, Nicorici D, Hautaniemi S, Alazzouzi H, Mecklin JP, Jarvinen H, Hemminki A, Astola J, Schwartz S Jr, Aaltonen LA
    Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer
    Gastroenterology. 2005 Sep;129(3):874-84
  18. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen A-S, Pajunen M, Rauhala M, Kaleva-Kerola J, Leinonen M, Elomaa I, Isola J
    Trastuzumab in Combination with Vinorelbine or Docetaxel as Adjuvant Treatment of Breast Cancer with HER-2 Gene Amplification
    New Eng J Med, 2006; 354: 809-20.
  19. Kangasniemi L, Kiviluoto T, Kanerva A, Raki M, Ranki T, Sarkioja M, Wu H, Marini F, Hockerstedt K, Isoniemi H, Alfthan H, Stenman U-H, Curiel DT, Hemminki A
    Capsid modified adenoviruses for increasing gene transfer and oncolytic potency in clinical patient samples and in novel orthotopic models of disseminated gastric cancer
    Clin Cancer Res, 2006;12: 3137-44.
  20. Bauerschmitz GJ, Guse K, Kanerva A, Yamamoto M, Nettelbeck DM, Hakkarainen T, Dall P, Curiel DT, Hemminki A
    Conditionally replicating adenoviruses featuring the Cox-2 tumor specific promoter and E1A transcomplementation for selective oncolysis of ovarian cancer cells
    Mol Ther, 2006 Aug;14(2):164-74.
  21. Kangasniemi L, Kiviluoto T, Kanerva A, Raki M, Ranki T, Sarkioja M, Wu H, Marini F, Hockerstedt K, Isoniemi H, Alfthan H, Stenman U-H, Curiel DT, Hemminki A.
    Capsid modified adenoviruses for increasing gene transfer and oncolytic potency in clinical patient samples and in novel orthotopic models of disseminated gastric cancer.
    Clin Cancer Res, 2006; 12: 3137-44.
  22. Hemminki A, Kellokumpu-Lehtinen P-L.
    The impact of the EU clinical trials directive on clinical cancer research.
    BMJ 2006; 332: 501-2.
  23. Eriksson M, Bauerschmitz G, Guse K, Virkkunen P, Tarkkanen M, Hakkarainen T, Tanner M, Kanerva A, Desmond RA, Pesonen S, Hemminki A.
    Oncolytic adenoviruses kill breast cancer stem cells.
    Mol Ther, 2007;15:2088-93.
  24. Bauerschmitz GJ, Kangasniemi L, Pesonen S, Eriksson M, Porten M, Herrmann I, Virkkunen P, Tarkkanen M, Ranki T, Hakkarainen T, Kanerva A, Rein D & Hemminki A.
    Tissue specific promoter controlled oncolytic adenoviruses for killing of CD44+CD24-/low breast cancer cells.
    Cancer Res, 2008;68:5533-9.
  25. Hakkarainen T, Rajecki M, Sarparanta M, Tenhunen M, Airaksinen A, Kairemo K, Hemminki A.
    Targeted radiotherapy for prostate cancer by combining oncolytic adenovirus and hNIS mediated radioiodide therapy.
    Clin Cancer Res 2009;15:5396-403.
  26. Strauss R, Sova P, Liu Y, Li Z, Tuve S, Pritchard D, Brinkkoetter P, Möller T, Wildner O, Pesonen S, Hemminki A, Urban N, Drescher C, Lieber A.
    The epithelial architecture of ovarian cancer cells mediates resistance to oncolytic adenoviruses.
    Cancer Res, 2009; 69:5115-25.
  27. Joensuu G, Joensuu T, Nokisalmi P, Isola J, Ruutu M, Joensuu H, Kouri M, Pesonen A, Hemminki A.
    A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with non-metastatic prostate cancer.
    Int J Radiat Oncol Biol Phys, in press 2009.
  28. Joensuu H, Kellokumpu-Lehtinen P-L, Huovinen R, Jukkola-Vuorinen A, Asola R, Kokko R, Ahlgren J, Auvinen P, Hemminki A, Paija O, Möykkynen K, Helle L, Nuortio L, Villman K, Nilsson G, Lahtela S-L, Lehtiö K, Salminen T, Pajunen M, Poikonen P, Nyandoto P, Andreasson I, Kataja V, Malmberg L, Bono P, Tanner M, Leinonen M, Lindman H for the FinXX Study Investigators.
    Adjuvant capecitabine for early breast cancer.
    Lancet Oncol, 2009;10:1145-51.
  29. Wang H, Liu Y, Li Z, Fan X, Hemminki A, Lieber A.
    Recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.
    Blood, in press 2009.
  30. Pesonen S, Nokisalmi P, Escutenaire S, Särkioja M, Raki M, Cerullo V, Kangasniemi L, Laasonen L, Ribacka C, Guse K, Haavisto E, Oksanen M, Rajecki M, Helminen A, Ristimäki A, Karioja-Kallio A, Karli E, Kantola T, Bauerschmitz G, Kanerva A, Joensuu T & Hemminki A.
    Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.
    Gene Ther, in press 2009.
PHD THESES
MASTER THESES